Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anticoagulation may improve survival in patients with cancer through an antitumor effect in addition to the perceived antithrombotic effect. OBJECTIVES: To evaluate the efficacy and safety of parenteral anticoagulants in patients with cancer with no therapeutic or prophylactic indication for anticoagulation. SEARCH STRATEGY: A comprehensive search included (1) an electronic search (February 2010) of the following databases: Cochrane Central Register of Controlled Trials (CENTRAL) Issue 1, 2010, MEDLINE, EMBASE and ISI the Web of Science; (2) handsearch of conference proceedings; (3) checking of references of included studies; and (4) use of the 'related citation' feature in PubMed. SELECTION CRITERIA: Randomized controlled trials (RCTs) assessing the benefits and harms of parenteral anticoagulation in patients with cancer but no therapeutic or prophylactic indication for anticoagulation. DATA COLLECTION AND ANALYSIS: Using a standardized form we extracted in duplicate data on methodological quality, participants, interventions and outcomes of interest including all-cause mortality, symptomatic thromboembolism, major bleeding, minor bleeding and quality of life (QoL). MAIN RESULTS: Of 8187 identified citations, nine RCTs enrolling 2857 patients fulfilled the inclusion criteria. In all included RCTs the intervention consisted of heparin (either unfractionated heparin or low molecular weight heparin). Overall, the effect of heparin therapy on mortality was not statistically significant at 12 months (risk ratio (RR) 0.93; 95% CI 0.85 to 1.02) but it was statistically significant at 24 months (RR 0.92; 95% CI 0.88 to 0.97). Heparin therapy was associated with a statistically and clinically important reduction in venous thromboembolism (RR 0.55; 95% CI 0.37 to 0.82). There were no statistically significant effects on major bleeding (RR 1.30; 95% CI 0.59 to 2.88), minor bleeding (RR 1.05; 95% 0.75 to 1.46) or QoL. The quality of evidence was high for symptomatic venous thromboembolism, moderate for mortality, major bleeding and minor bleeding, and low for QoL. AUTHORS' CONCLUSIONS: Heparin was associated with a significant reduction of death at 24 months but not 12 months. It was also associated with a reduction in venous thromboembolism but based on the RCTs in this review it had no significant effect on major bleeding, minor bleeding or QoL. Future research should further investigate the survival benefit of different types of anticoagulants in patients with different types and stages of cancer. The decision for a patient with cancer to start heparin therapy for survival benefit should balance the benefits and downsides and integrate the patient's values and preferences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163
Methods to estimate the between‐study variance and its uncertainty in meta‐analysis
Veroniki, A. A., Jackson, D., Viechtbauer, W., Bender, R., Bowden, J., Knapp, G., Kuss, O., Higgins, J. P., Langan, D., & Salanti, G. (2016) · Research Synthesis Methods · doi:10.1002/jrsm.1164 · Cited by 1,685
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113697 · Cited by 983
Living systematic review: 1. Introduction-the why, what, when, and how
Elliott, J. H., Synnot, A., Turner, T., Simmonds, M., Akl, E. A., McDonald, S., Salanti, G., Meerpohl, J., MacLehose, H., Hilton, J., et al. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.08.010 · Cited by 655
Self-citationRandom-Effects Meta-analysis of Inconsistent Effects: A Time for Change
Cornell, J. E., Mulrow, C. D., Localio, R., Stack, C. B., Meibohm, A. R., Guallar, E., & Goodman, S. N. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2886 · Cited by 453
Dettori, J. (2011) · Evidence-Based Spine-Care Journal · doi:10.1055/s-0030-1267080 · Cited by 336
Living systematic reviews: 4. Living guideline recommendations.
Akl, E. A., Meerpohl, J. J., Elliott, J., Kahale, L. A., Schünemann, H. J., Agoritsas, T., Hilton, J., Perron, C., Akl, E., Hodder, R., et al. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.08.009 · Cited by 328
Self-citationAkl, E. A., Sun, X., Busse, J. W., Johnston, B. C., Briel, M., Mulla, S., You, J. J., Bassler, D., Lamontagne, F., Vera, C., et al. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.04.015 · Cited by 179
Self-citationGuyatt, G. H., Ebrahim, S., Alonso-Coello, P., Johnston, B. C., Mathioudakis, A. G., Briel, M., Mustafa, R. A., Sun, X., Walter, S. D., Heels-Ansdell, D., et al. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.05.005 · Cited by 163
Self-citation
Cited by
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Lyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Farge, D., Frere, C., Connors, J. M., Ay, C., Khorana, A. A., Munoz, A., Brenner, B., Kakkar, A., Rafii, H., Solymoss, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30336-5 · Cited by 651
Interpreting results and drawing conclusions
Schünemann, H. J., Vist, G. E., Higgins, J. P., Santesso, N., Deeks, J. J., Glasziou, P., Akl, E. A., Guyatt, G. H., & on behalf of the Cochrane GRADEing Methods Group (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch15 · Cited by 595
Self-citation
Metadata
- Authors
- Akl, E. A., Gunukula, S., Barba, M., Yosuico, V. E. D., van Doormaal, F. F., Kuipers, S., Middeldorp, S., Dickinson, H. O., Bryant, A., & Schünemann, H.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2011-04-13
- Volume
- 10
- Issue
- 4
- Pages
- CD006466-CD006466
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2103969621
- Cited by
- 118
- References
- 12
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. https://app.cochat.ai/papers/10.1002/14651858.cd006652.pub3
- The paper
- Akl, E. A., Gunukula, S., Barba, M., Yosuico, V. E. D., van Doormaal, F. F., Kuipers, S., Middeldorp, S., Dickinson, H. O., Bryant, A., & Schünemann, H. (2011). Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd006652.pub3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.